Atorvastatin inhibits inflammatory hypernociception
Open Access
- 1 September 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 149 (1) , 14-22
- https://doi.org/10.1038/sj.bjp.0706836
Abstract
Background and purpose: Atorvastatin is an inhibitor of the enzyme 3‐hydroxyl‐3‐methylglutaryl coenzyme A reductase used to prevent coronary heart disease. We have studied the analgesic effect of atorvastatin in inflammatory models in which a sequential release of mediators (bradykinin, (BK), tumour necrosis factor‐α (TNF‐α), interleukin‐1β (IL‐1β) and the chemokine, KC/CXCL) links the stimulus with release of directly acting hypernociceptive mediators such as prostaglandin E2 (PGE2). Experimental approach: The effects of orally administered atorvastatin on inflammatory mechanical hypernociception in mouse paws were evaluated with an electronic pressure‐meter. Cytokines and PGE2 were measured by ELISA and RIA. Key results: Treatment with atorvastatin for 3 days dose‐dependently reduced hypernociception induced by lipopolysaccharide (LPS) or that following antigen challenge in sensitized animals. Atorvastatin pre‐treatment reduced hypernociception induced by bradykinin and cytokines (TNF‐α, IL‐1β and KC), and the release of IL‐1β and PGE2 in paw skin, induced by lipopolysaccharide. The antinociceptive effect of atorvastatin on LPS‐induced hypernociception was prevented by mevalonate co‐treatment without affecting serum cholesterol levels. Hypernociception induced by PGE2 was inhibited by atorvastatin, suggesting intracellular antinociceptive mechanisms for atorvastatin. The antinociceptive effect of atorvastatin upon LPS‐ or PGE2‐induced hypernociception was prevented by non‐selective inhibitors of nitric oxide synthase (NOS) but not by selective inhibition of inducible NOS or in mice lacking this enzyme. Conclusions and implications: Antinociceptive effects of atorvastatin depend on inhibition of cytokines and prostanoid production and on stimulation of NO production by constitutive NOS. Our study suggests that statins may constitute a novel class of analgesic drugs. British Journal of Pharmacology (2006) 149, 14–22. doi:10.1038/sj.bjp.0706836Keywords
This publication has 75 references indexed in Scilit:
- Atorvastatin Reduces the Expression of Prostaglandin E2 Receptors in Human Carotid Atherosclerotic Plaques and Monocytic CellsJournal of Cardiovascular Pharmacology, 2006
- Statins differ in their ability to block NF-kB activation in human blood monocytesInt. Journal of Clinical Pharmacology and Therapeutics, 2003
- Anti-inflammatory and immunomodulatory effects of statinsKidney International, 2003
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in MiceStroke, 2001
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cellsLife Sciences, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorsThe American Journal of Cardiology, 1995
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- A peripheral sympathetic component in inflammatory hyperalgesiaEuropean Journal of Pharmacology, 1987